Pulmonary Sarcoidosis Clinical Trial
Official title:
Comparison of the Effects of One-Legged and Two-Legged Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis
Pulmonary rehabilitation is a key element in the management of people with chronic respiratory disease. A properly followed supervised physical training program in sarcoidosis is safe and has no absolute contraindications. Fatigue can also be associated with sarcoidosis for different reasons. Individualized rehabilitation training can improve the symptoms of patients with sarcoidosis. There is no study in the literature investigating the effectiveness of one-legged exercises that reduce peripheral muscle use, in patients with sarcoidosis. In our study, these two exercise methods will be compared by applying one-legged exercise training and two-legged exercise training. The effect of one-legged exercise training on exercise capacity and fatigue in sarcoidosis patients will be examined. The primary aim of our study is to compare the effects of one-legged exercise training, which is a current exercise approach, and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis. The secondary aim is to examine the effect of this exercise training on peripheral muscle strength and quality of life parameters.
Pulmonary rehabilitation is a key element in the management of individuals with chronic respiratory disease. A properly followed supervised physical training program in sarcoidosis is safe and has no absolute contraindications. Fatigue may be associated with different causes in sarcoidosis. Individualized rehabilitation practices can improve the symptoms of patients with sarcoidosis. There is no study in the literature investigating the effectiveness of one-legged exercises that reduce peripheral muscle use in patients with sarcoidosis. In our study, these two exercise methods will be compared by applying one-legged exercise training and two-legged exercise training. 26 patients will be randomly divided into 2 groups (n1=n2=13). While one group will receive one-legged cycling ergometer training, the other group will receive two-legged cycling ergometer training. After 8 weeks of exercise training, patients will be evaluated with, Pulmonary Function Test, Six-Minute Walk Test, Endurance Shuttle Walk test, Fatigue Assessment Scale, Multidimensional Fatigue Inventory, Blood Lactate Level (with lactate device), Medical Research Council Dyspnea Scale, Handheld dynamometer, St. George's Respiratory Questionnaire. The effect of one-legged exercise training on exercise capacity and fatigue in sarcoidosis patients will be examined. The primary aim of our study is to compare the effects of one-legged exercise training, which is a current exercise approach, and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis. The secondary aim is to examine the effect of this exercise training on peripheral muscle strength and quality of life parameters. The completion of the study will contribute to the determination of the content of the exercise programs to be applied in sarcoidosis patients and will reveal the effectiveness of one-legged exercise training, which is a current exercise method, in sarcoidosis patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04064242 -
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
|
Phase 2 | |
Terminated |
NCT00262132 -
Mycophenolate for Pulmonary Sarcoidosis
|
Phase 3 | |
Recruiting |
NCT05415137 -
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
|
Phase 3 | |
Recruiting |
NCT00001532 -
Role of Genetic Factors in the Development of Lung Disease
|
||
Completed |
NCT04318392 -
Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
|
||
Active, not recruiting |
NCT03755245 -
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
|
N/A | |
Completed |
NCT01587001 -
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
|
N/A | |
Recruiting |
NCT05890729 -
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT02824419 -
Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT06205121 -
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
|
Phase 2 | |
Completed |
NCT02200146 -
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).
|
Phase 3 | |
Terminated |
NCT01732211 -
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
|
Phase 2 | |
Enrolling by invitation |
NCT06169397 -
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
|
Phase 2 | |
Not yet recruiting |
NCT05247554 -
Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis
|
Phase 3 | |
Completed |
NCT03599414 -
CASPA: CArdiac Sarcoidosis in PApworth
|
||
Recruiting |
NCT02188017 -
Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)
|
Phase 4 | |
Recruiting |
NCT06113991 -
Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
|
||
Completed |
NCT01169038 -
Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
|
Phase 1 | |
Completed |
NCT00701207 -
Study of Nicotine Patches in Patients With Sarcoidosis
|
Early Phase 1 | |
Completed |
NCT03824392 -
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
|
Phase 1/Phase 2 |